Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Anticancer Res ; 37(4): 2025-2031, 2017 04.
Article in English | MEDLINE | ID: mdl-28373477

ABSTRACT

BACKGROUND/AIM: Complete resection, surgical expertise and individualization of patient management in comprehensive oncology centres result in better clinical outcomes in patients presenting with retroperitoneal sarcomas. PATIENTS AND METHODS: Clinical outcomes of primary and recurrent retroperitoneal sarcoma resections performed between January 2002 and December 2016 in two large surgical oncology, but non-sarcoma specialist centers, were reviewed to determine the efficacy of complete surgical resection as the principle instrument for treatment. The histological type, tumor size and grade, as well as organ resection, were recorded and subsequently reviewed. RESULTS: Our study included 108 cases of sarcoma resection (60 first-time, 38 second-time and 10 third-time laparotomies) in 60 patients (35 males and 25 females). Most patients had complete resection: 57 had a macroscopically complete (R0/R1) resection and three had R2 resection. The 90-day mortality rate was zero and morbidity was minimal. Five- and 10-year overall survival (OS) rates were 88% and 79%, respectively, whereas the corresponding disease-free survival (DFS) rates were 65% and 59%, respectively. High-grade tumors were associated with decreased DFS (hazard ratio(HR)=3.35; 95% confidence interval(CI)=1.23-9.10; p=0.018) and decreased OS (HR=7.18; 95% CI=1.50-34.22; p=0.013). CONCLUSION: Complete surgical resection of retroperitoneal sarcomas combined with individualized patient management when offered by experienced surgical oncology teams, adhering to international guidelines, can succeed in providing patients with good long-term outcomes, comparable to those achieved at sarcoma-specialist centers.


Subject(s)
Neoplasm Recurrence, Local/surgery , Retroperitoneal Neoplasms/surgery , Sarcoma/surgery , Disease Management , Female , Follow-Up Studies , Humans , Male , Middle Aged , Neoplasm Grading , Neoplasm Recurrence, Local/pathology , Prognosis , Retroperitoneal Neoplasms/pathology , Retrospective Studies , Sarcoma/pathology , Survival Rate
2.
Fertil Steril ; 92(1): 250-5, 2009 Jul.
Article in English | MEDLINE | ID: mdl-18678372

ABSTRACT

OBJECTIVE: To evaluate basal metabolic rate (BMR) in women with PCOS and to determine its association with insulin resistance (IR). DESIGN: Prospective assessment of BMR in women with PCOS. SETTING: Outpatient clinic of the Division of Reproductive Endocrinology. PATIENT(S): The study included 91 Greek women with PCOS and biochemical hyperandrogenemia, with mean age 24.03 +/- 0.55 years and mean body mass index (BMI) 26.67 +/- 0.69 kg/m(2), and 48 matched regularly menstruating women, with mean age 26.33 +/- 0.93 years and mean BMI 23.35 +/- 0.85 kg/m(2), as control subjects. INTERVENTION(S): Assessment of BMR by indirect calorimetry, IR by HOMA and QUICKI indices, fasting insulin, and fasting glucose/insulin ratio. MAIN OUTCOME MEASURE(S): Reduced BMR in PCOS with or without IR. RESULT(S): Adjusted BMR was 1,868 +/- 41 kcal/day in the control group, 1,445.57 +/- 76 in all PCOS women, 1,590 +/- 130 in PCOS women without IR and 1,116 +/- 106 in PCOS women with IR. Adjusted BMR showed a statistically significant difference between women with PCOS and control subjects, with lowest values in the group of PCOS women with IR, even after adjusting all groups for age and BMI. CONCLUSION(S): Women with PCOS, particularly those with IR, present a significantly decreased BMR.


Subject(s)
Basal Metabolism/physiology , Body Composition , Hyperandrogenism/physiopathology , Insulin Resistance/physiology , Polycystic Ovary Syndrome/physiopathology , Adult , Female , Greece , Humans , Hyperandrogenism/complications , Polycystic Ovary Syndrome/complications , Polycystic Ovary Syndrome/epidemiology , Prospective Studies , Reference Values , Young Adult
3.
Thyroid ; 17(12): 1257-9, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17988198

ABSTRACT

Fibroids or leiomyomas or myomas of the uterus are the most common benign gynecologic disease, while fibroadenomas of the breast are most frequently seen in young women, usually within 20 years after puberty. Multiple tumors in one or both breasts are found in 10-15% of patients. Single thyroid nodules are much more common in women than in men, and their prevalence increases with age. The aim of the present study was to determine cross-sectionally the incidence of solitary thyroid nodules and fibroadenomas of the breast in women with uterine fibroids. In women with uterine adenomas, the frequency of fibroadenomas of the breast was 65% and of thyroid nodules was 38.7%, while in women with a normal uterus, the frequency was 35% and 20%, respectively. Therefore, women with uterine fibroids have an increased incidence of thyroid nodules (t = 4.68, p = 0.030) and of fibroadenomas of the breast (t = 11.74, p = 0.001).


Subject(s)
Breast Neoplasms/complications , Fibroadenoma/complications , Leiomyoma/complications , Thyroid Nodule/complications , Adult , Breast Neoplasms/diagnosis , Case-Control Studies , Cross-Sectional Studies , Female , Fibroadenoma/diagnosis , Humans , Incidence , Leiomyoma/diagnosis , Middle Aged , Risk Factors , Thyroid Nodule/diagnosis
4.
Fertil Steril ; 88(5): 1311-7, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17603054

ABSTRACT

OBJECTIVE: To correlate the presence of renal agenesis/dysgenesis to the prevalence of KAL1 gene defects in patients with sporadic Kallmann syndrome (KS). DESIGN: Prospective assessment of renal structure and DNA sequence analysis of the KAL1 gene. SETTING: Outpatient clinics of the divisions of endocrinology of university hospitals. PATIENT(S): Sixteen male patients with sporadic KS. INTERVENTION(S): Assessment of renal structure by abdominal ultrasounds scans and DNA extraction, polymerase chain reaction amplification, and DNA sequence analysis of all 14 exons of the KAL1 gene. MAIN OUTCOME MEASURE(S): KAL 1 gene structure and presence of renal dysgenesis. RESULT(S): Renal dysgenesis was identified in only two of 16 KS patients. Genetic defects were found in only two patients with KS, that is, in those with the identified renal dysgenesis. The first gene defect was identified in a patient with associated right renal agenesis who had two point mutations in the KAL1 gene: the first was a G to A transition in exon 11, turning codon 514 encoding glutamic acid into lysine; and the second was a G to A transition in exon 13, turning codon 660 encoding alanine into threonine. The second gene defect was identified in a patient with ichthyosis, right renal agenesis, and mirror movements of the upper limbs (synkinesia) and comprised a deletion of exons 5-10 of the KAL1 gene and a complete deletion of the steroid sulphatase gene. CONCLUSION(S): The phenotype of renal agenesis/dysgenesis strongly indicates the existence of KAL1 gene defects in the genotype of patients with sporadic KS, providing evidence for the X-linked mode of inheritance and offering the opportunity for genetic counseling.


Subject(s)
Extracellular Matrix Proteins/genetics , Kallmann Syndrome/genetics , Kidney/abnormalities , Nerve Tissue Proteins/genetics , DNA Mutational Analysis/methods , Extracellular Matrix Proteins/deficiency , Humans , Kidney/growth & development , Kidney/physiology , Male , Mutation , Nerve Tissue Proteins/deficiency , Polymorphism, Genetic/genetics , Prospective Studies , Sequence Deletion
6.
Gynecol Endocrinol ; 22(12): 704-9, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17162714

ABSTRACT

Combined pituitary hormone deficiency (CPHD) is a rare disorder resulting from an impaired pituitary function due to different causes, characterized by impaired secretion of growth hormone (GH) and one or more of the other anterior pituitary hormones. To date, 16 distinct human Prophet of Pit-1 (Prop1) gene mutations have been identified in patients with CPHD, inducing a phenotype involving GH, follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin and thyroid-stimulating hormone (TSH), and rarely adrenocorticotropic hormone, deficiency. Herein we present two siblings of different sexes from a family with parental consanguinity presenting the 301-302delAG mutation in the Prop1 gene. The female presented failure of growth from the age of 6 years and was treated for 10 years with GH, ending in a final height (standard deviation score) of -0.28. TSH deficiency was manifested after the initiation of GH and was treated with thyroxine while puberty was initiated with conjugated estrogens. The male presented TSH deficiency since childhood, treated with thyroxine, and growth failure at the age of 14 years, treated for a period of 2 years with GH. Puberty was initiated with increasing doses of testosterone, while human chorionic gonadotropin was added in order to achieve increased testicular volume. In conclusion, these two siblings of different sexes with CPHD carrying the 301-302delAG mutation in the Prop1 gene presented a variable phenotype characterized by GH, TSH, LH and FSH deficiency.


Subject(s)
Dwarfism, Pituitary/genetics , Gonadotropins, Pituitary/deficiency , Growth Hormone/deficiency , Homeodomain Proteins/genetics , Hypogonadism/genetics , Adolescent , Consanguinity , Female , Frameshift Mutation/genetics , Frameshift Mutation/physiology , Humans , Male , Mutation , Pedigree , Siblings
7.
Gynecol Endocrinol ; 22(4): 185-9, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16723304

ABSTRACT

In postmenopausal women with estrogen receptor (ER)-positive breast cancer, long-term tamoxifen administration has proved beneficial after surgical treatment and subsequent chemotherapy. One of the major adverse effects of tamoxifen is the development of endometrial pathology (polyps, endometrial hyperplasia and endometrial cancer). PvuII and XbaI polymorphisms of the estrogen receptor-alpha gene (ERalpha) and RsaI and AluI polymorphisms of the estrogen receptor-beta gene (ERbeta) have been associated with breast cancer. Thus the present study aimed to identify whether ER gene polymorphisms are associated with breast cancer stage or endometrial responsiveness to long-term tamoxifen treatment in 87 postmenopausal, tamoxifen-treated women with ER-positive breast cancer. The mean age of the patients was 58.7 +/- 4.7 years and the mean duration of tamoxifen treatment was 3.9 +/- 1.1 years. At diagnosis, the stage of breast cancer was determined as follows: 29 women (32%) at Stage I, 49 (58%) at Stage II and 9 (10%) at Stage III. The frequency distributions of the estrogen receptor polymorphisms in all women with breast cancer were not different from those predicted by the Hardy-Weinberg equilibrium hypothesis (p > 0.10). None of the ER polymorphisms studied was linked to either the presence of endometrial pathology or the stage of breast cancer.


Subject(s)
Breast Neoplasms/genetics , Endometrium/pathology , Estrogen Receptor alpha/genetics , Estrogen Receptor beta/genetics , Polymorphism, Genetic/genetics , Selective Estrogen Receptor Modulators/adverse effects , Tamoxifen/adverse effects , Breast Neoplasms/pathology , Endometrial Neoplasms/etiology , Endometrial Neoplasms/pathology , Female , Genetic Predisposition to Disease , Humans , Middle Aged , Neoplasm Staging/adverse effects
8.
Fertil Steril ; 84(6): 1762-5, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16359986

ABSTRACT

The study included 26 patients with idiopathic hypogonadotropic hypogonadism (24 sporadic and 2 familial). The Pro146Ser mutation was identified in the gonadotropin-releasing hormone receptor (GnRHR) gene in two sisters as well as in their mother, and one polymorphism in the GnRH1 gene (the Trp16Ser) was identified in four patients. No mutations in transcription factor-binding sites of their promoters were identified. Three patients (one male and two sisters) were found with resistance to GnRH action. No mutations were identified in the male, whereas in the females the mutation Pro146Ser in the GnRHR was identified in heterozygosity.


Subject(s)
Gonadotropin-Releasing Hormone/metabolism , Hypogonadism/genetics , Promoter Regions, Genetic/genetics , Receptors, LHRH/genetics , Receptors, LHRH/metabolism , Adult , Family Health , Female , Heterozygote , Humans , Hypogonadism/physiopathology , Male , Polymorphism, Genetic
10.
Acta Derm Venereol ; 85(5): 389-93, 2005.
Article in English | MEDLINE | ID: mdl-16159728

ABSTRACT

Heat shock protein 27 (Hsp27), apart from its protective function in response to stress, is implicated in the regulation of cell growth, differentiation and apoptosis. Data on the expression of Hsp27 in the developing human epidermis are sparse and partially conflicting. Thus, the purpose of the present study was to investigate Hsp27 expression during the morphogenesis of human epidermis. Skin biopsies and dispase-separated epidermal sheets obtained from 7 human embryos (7 and 8 weeks estimated gestational age, EGA), from 79 human fetuses (9-23 weeks EGA) and from 10 healthy adult volunteers were investigated by immunohistochemistry and Western blotting, respectively. The earliest detection of Hsp27 expression was found by immunohistochemistry at the 12th week EGA (basal and intermediate layer) and by Western blotting at the 9th week EGA. From the 16th to the 23rd week EGA immunoreactivity was not detectable in the basal layer, whereas in the overlying layers it revealed a differentiation-related pattern. The simultaneous onset of epidermal stratification and Hsp27 expression (9th week EGA) and the alterations of the latter in the subsequent stages of development, suggest that this stress protein may be involved in the molecular events underlying human epidermal morphogenesis.


Subject(s)
Epidermis/embryology , Epidermis/metabolism , Heat-Shock Proteins/metabolism , Adult , Blotting, Western , Gestational Age , Humans , Immunohistochemistry , Morphogenesis
11.
J Clin Endocrinol Metab ; 90(11): 6022-7, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16118332

ABSTRACT

CONTEXT: Elite gymnasts are subjected to intense training, which may alter pubertal development. OBJECTIVE: The objective of the investigation was to study the impact of gymnastics on pubertal development in rhythmic (RGs) and artistic gymnasts (AGs). DESIGN: Evaluation of somatometric parameters, pubertal stage, and intensity of training in the competition field were studied. SETTING: The study was conducted at European and world championships of years 1997-2004. SUBJECTS: Subjects included 433 elite RGs and 427 AGs, aged 11-23 yr. INTERVENTION: There were no interventions. MAIN OUTCOME MEASURES: Mean chronological and bone ages of each pubertal stage and their relation to the intensity of training were measured. RESULTS: AGs and RGs showed a delay in skeletal maturation (Delta age-bone age, 2.13 and 1.28, respectively; P < 0.001). AGs were subjected to higher levels of physical training. Thelarche occurred at 12.9 yr for RGs and 13.2 yr for AGs (P = 0.003) and pubarche at 12.5 and 12.9 yr, respectively (P = 0.002). Puberty was delayed but normally progressed. AGs entered each pubertal stage later than RGs. The delay was influenced by the amount of energy output. Menarcheal age was 14.6 yr for RGs and 14.9 yr for AGs. Menarche was influenced in AGs by bone age (b = 0.333; t = 2.521; P = 0.020), pubarche (b = 0.322; t = 2.401; P = 0.026), and body fat (b = -0.458; t = -3.412; P = 0.003) and in RGs by bone age (b = 0.378; t = 3.689; P < 0.001) and pubarche (b = 0.525; t = 6.017; P < 0.001). CONCLUSION: In RGs and AGs, pubertal development was shifted to a later age, maintaining a normal rate of progression, which followed the bone age. AGs, who were exposed to a greater and more sustained energy output than RGs, presented a more pronounced delay in both skeletal maturation and pubertal development.


Subject(s)
Gymnastics , Physical Education and Training , Puberty, Delayed , Adolescent , Adult , Child , Cross-Sectional Studies , Female , Humans , Menarche , Regression Analysis , Sexual Maturation
12.
J Biomed Mater Res B Appl Biomater ; 72(2): 368-72, 2005 Feb 15.
Article in English | MEDLINE | ID: mdl-15578649

ABSTRACT

Our objective was to evaluate the effectiveness of a late or emergency (salvage) cerclage after tissue reinforcement with Pelvicol natural implant, in preventing premature rupture of the fetal membranes and advancing pregnancy prolongation. A flat sheet of Pelvicol, a sterile acellular natural (porcine) implant was used in an emergency cerclage to reinforce the thin tissues of a widely dilated cervix in a 24 weeks' twin gestation with prolapsed unruptured membranes, without contractions, placental abruption, or intrauterine infection. The gestation was extended to 38 weeks without any complications. Two live healthy newborns were delivered by elective cesarean section due to a nonvertex/vertex presentation. The implant was found to be attached almost unaltered firmly on the outer surface of the membrane sac just opposite to the internal os. It seems that Pelvicol is safe and apparently protects by clothing the thinned, soft, and weak wall of a significantly dilated uterine cervix and the bulging or protruding gestational membranes. It also reinforces and strengthens the tissue thickness and resistance, rendering more accurate and safe the otherwise delicate and risky late cerclage. The technique gives hopes that it can help in pregnancy prolongation.


Subject(s)
Bioprosthesis , Cerclage, Cervical/methods , Skin Transplantation/methods , Adult , Collagen , Elastin , Female , Humans , Pregnancy , Pregnancy Complications/prevention & control , Pregnancy Complications/surgery , Pregnancy Outcome , Prosthesis Implantation , Salvage Therapy/methods
13.
Curr Top Med Chem ; 4(4): 487-98, 2004.
Article in English | MEDLINE | ID: mdl-14965315

ABSTRACT

Until recently elevated blood pressure was considered as a hemodynamic entity representing an increase in workload for the heart and the arterial tree. Control of hypertension meant hemodynamic unloading, through inhibition of vasoconstrictor pathways, principally renin-angiotensin system and sympathetic system. In recent years however a new pharmacological approach has evolved as a result of (i) the dissociation of endothelial dysfunction and vascular pathology from increased blood pressure; (ii) the recognition that endothelial dysfunction regards not only the vascular reactivity, but also promotes atherosclerosis and thrombosis; and (iii) an improved understanding of the complexity of local-tissue renin angiotensin system and of the vasodilatory and cytoprotective role of natriuretic peptides. This has led to a reconsideration of existing medicines in terms of specification on endothelial function, more rationalized application of drugs and search for new compounds targeting both vasodilatory and anti-proliferative pathways. Examples include beta1-adrenergic antagonists, such as Nebivolol and Carvedilol, and vasopeptidase inhibitors, such as Omapatrilat, that inhibit simultaneously the angiotensin converting enzyme and neutral endopeptidase. Furthermore the identification of genetic polymorphisms in the effectors involved in the pathophysiology of hypertension or in the response to anti-hypertensive drugs, such as the p22phox subunit of NADPH oxidase, alpha-adducin or adrenergic receptors, has promoted the prospective of both better understanding of hypertension and individualized strategies for its treatment.


Subject(s)
Antihypertensive Agents/pharmacology , Hypertension/drug therapy , Adrenergic beta-Antagonists/pharmacology , Angiotensins/metabolism , Antihypertensive Agents/adverse effects , Antihypertensive Agents/therapeutic use , Cardiovascular System/metabolism , Endothelium/drug effects , Endothelium/metabolism , GTP-Binding Proteins/metabolism , Humans , Hypertension/genetics , Hypertension/metabolism , Pharmacogenetics , Renin-Angiotensin System/drug effects , Vasculitis/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...